Last updated: March 21, 2024
Sponsor: Hamad Medical Corporation
Overall Status: Active - Recruiting
Phase
N/A
Condition
Gastroenteritis
Treatment
Molecular method (PCR)
Clinical Study ID
NCT03046342
14-00045
Ages 3-14 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- All acute gastroenteritis patients between 3 months to 14 years presenting to PECcenters with acute diarrhea+/- vomiting with or without fever
Exclusion
Exclusion Criteria:
- Cases of vomiting +/- fever only without diarrhea
- Suspicion of surgical abdomen
- Bile stained vomitus
- Mal-absorption diseases as cystic fibrosis, celiac disease or increased secretion asdisaccharides deficiency
- Cases of Inflammatory bowel disease
- Antibiotic associated diarrhea
- Patients with immune deficiency
- Patients with chronic diarrhea (>2 weeks of diarrhea)
- Patients receiving long term medication for any disease
Study Design
Total Participants: 3000
Treatment Group(s): 1
Primary Treatment: Molecular method (PCR)
Phase:
Study Start date:
March 10, 2015
Estimated Completion Date:
December 10, 2024
Study Description
Connect with a study center
Hamad medical corporation
Doha, 3050
QatarActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.